BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 27192872)

  • 1. [DDX5 is a novel targeting protein of tumor suppressor ARF].
    Tago K; Funakoshi-Tago M
    Seikagaku; 2016 Apr; 88(2):207-10. PubMed ID: 27192872
    [No Abstract]   [Full Text] [Related]  

  • 2. Arf tumor suppressor disrupts the oncogenic positive feedback loop including c-Myc and DDX5.
    Tago K; Funakoshi-Tago M; Itoh H; Furukawa Y; Kikuchi J; Kato T; Suzuki K; Yanagisawa K
    Oncogene; 2015 Jan; 34(3):314-22. PubMed ID: 24469041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. P19ARF and RasV¹² offer opposing regulation of DHX33 translation to dictate tumor cell fate.
    Zhang Y; Saporita AJ; Weber JD
    Mol Cell Biol; 2013 Apr; 33(8):1594-607. PubMed ID: 23401854
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNA helicase DDX5 is a p53-independent target of ARF that participates in ribosome biogenesis.
    Saporita AJ; Chang HC; Winkeler CL; Apicelli AJ; Kladney RD; Wang J; Townsend RR; Michel LS; Weber JD
    Cancer Res; 2011 Nov; 71(21):6708-17. PubMed ID: 21937682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interactive pathway of ARF-mdm2-p53].
    Lin J; Zhu MH
    Ai Zheng; 2003 Mar; 22(3):328-30. PubMed ID: 12654198
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Arf/p53 pathway in cancer and aging.
    Matheu A; Maraver A; Serrano M
    Cancer Res; 2008 Aug; 68(15):6031-4. PubMed ID: 18676821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The differential impact of p16(INK4a) or p19(ARF) deficiency on cell growth and tumorigenesis.
    Sharpless NE; Ramsey MR; Balasubramanian P; Castrillon DH; DePinho RA
    Oncogene; 2004 Jan; 23(2):379-85. PubMed ID: 14724566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The INK4a/ARF locus and human cancer.
    Enders GH
    Methods Mol Biol; 2003; 222():197-209. PubMed ID: 12710688
    [No Abstract]   [Full Text] [Related]  

  • 9. RUVBL2 is a novel repressor of ARF transcription.
    Xie C; Wang W; Yang F; Wu M; Mei Y
    FEBS Lett; 2012 Feb; 586(4):435-41. PubMed ID: 22285491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Delayed ageing through damage protection by the Arf/p53 pathway.
    Matheu A; Maraver A; Klatt P; Flores I; Garcia-Cao I; Borras C; Flores JM; Viña J; Blasco MA; Serrano M
    Nature; 2007 Jul; 448(7151):375-9. PubMed ID: 17637672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The DEAD box RNA helicases p68 (Ddx5) and p72 (Ddx17): novel transcriptional co-regulators.
    Fuller-Pace FV; Ali S
    Biochem Soc Trans; 2008 Aug; 36(Pt 4):609-12. PubMed ID: 18631126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ink4a/Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse.
    Khoo CM; Carrasco DR; Bosenberg MW; Paik JH; Depinho RA
    Proc Natl Acad Sci U S A; 2007 Mar; 104(10):3931-6. PubMed ID: 17360455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DNA (cytosine-5)-methyltransferase 1 as a mediator of mutant p53-determined p16(ink4A) down-regulation.
    Guo Z; Tsai MH; Shiao YH; Chen LH; Wei ML; Lv X; Gius D; Little JB; Mitchell JB; Chuang EY
    J Biomed Sci; 2008 Mar; 15(2):163-8. PubMed ID: 18038118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The TP53-ARF tumor suppressor pathway is frequently disrupted in large/cell anaplastic medulloblastoma.
    Frank AJ; Hernan R; Hollander A; Lindsey JC; Lusher ME; Fuller CE; Clifford SC; Gilbertson RJ
    Brain Res Mol Brain Res; 2004 Feb; 121(1-2):137-40. PubMed ID: 14969745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. When mutant p53 plays hide and seek: a new challenge for diagnosis and therapy?
    Soussi T; Hjortsberg L
    Trends Mol Med; 2009 Jan; 15(1):1-4. PubMed ID: 19097939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TRIP from ULF to ARF.
    Collado M; Serrano M
    Cancer Cell; 2010 Apr; 17(4):317-8. PubMed ID: 20385357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-aging activity of the Ink4/Arf locus.
    Matheu A; Maraver A; Collado M; Garcia-Cao I; Cañamero M; Borras C; Flores JM; Klatt P; Viña J; Serrano M
    Aging Cell; 2009 Apr; 8(2):152-61. PubMed ID: 19239418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDX5 promotes proliferation and tumorigenesis of non-small-cell lung cancer cells by activating β-catenin signaling pathway.
    Wang Z; Luo Z; Zhou L; Li X; Jiang T; Fu E
    Cancer Sci; 2015 Oct; 106(10):1303-12. PubMed ID: 26212035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest and cooperates with Ras in transformation.
    Damalas A; Kahan S; Shtutman M; Ben-Ze'ev A; Oren M
    EMBO J; 2001 Sep; 20(17):4912-22. PubMed ID: 11532955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ARF tumor suppression in the nucleolus.
    Maggi LB; Winkeler CL; Miceli AP; Apicelli AJ; Brady SN; Kuchenreuther MJ; Weber JD
    Biochim Biophys Acta; 2014 Jun; 1842(6):831-9. PubMed ID: 24525025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.